Trypanosoma brucei is a parasitic protozoan and the causative agent of African sleeping sickness in humans and nagana in African livestock. Sleeping sickness threatens over 60 million people in 36 countries of sub-Saharan Africa. As opposed to other parasitic organisms, trypanosomes synthesize phospholipids de novo. This makes the trypanosome phospholipids biosynthesis machinery a very attractive target for new drug design. Our lab is focused on TbLpn, a trypanosome lipin homologue that catalyzes the dephosphorylation of phosphatidic acid (PA) to diacylglycerol (DAG), with a potential role in phospholipid biosynthesis. In addition, as predicted from its in vivo interaction with a protein arginine methyltransferase (PRMT), we have shown that TbLpn contains methylated arginine residues. The genome of T. brucei predicts the presence of five PRMTs. Our goal is to determine, by using an antibody-based approach, whether any or several of these PRMTs are responsible for the methylation of TbLpn.
|Presenters:||Philip Bellomio (Undergraduate Student)
Rebecca Tobin (Undergraduate Student)
|Time:||9:20 am Session I|